Overview

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Status:
RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Phase:
PHASE2
Details
Lead Sponsor:
Akeso
Treatments:
Drug Therapy